New drug combo shows promise for tough head and neck cancers
NCT ID NCT00076310
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether adding the targeted drug Tarceva (erlotinib) to standard chemotherapy (cisplatin and docetaxel) can shrink tumors in people with head and neck cancer that has spread or returned. About 50 participants will receive the combination and be monitored for tumor response and side effects. The goal is to see if this approach is effective enough to warrant further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tarceva (erlotinib) combined with cisplatin and docetaxel chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced head and neck cancer that has spread or come back.
What could go wrong
This is a small, early-phase trial with only 50 participants. The added drug may increase side effects without improving outcomes, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States